Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13953179 | 1.00 | BTK (0.37) | BTKHRH3CHRM2CHRM4CHRM3 | |
| SCHEMBL8343602 | 0.87 | CHRNB2 (0.40) | CHRM2CHRM4CHRM3CYP3A4CYP1A2 | |
| SCHEMBL30684661 | 0.82 | HRH3 (0.37) | BTKHRH3CHRM2CHRM4CHRM3 | |
| SCHEMBL3640335 | 0.81 | SMN1; SMN2 (0.42) | BTKHRH3CHRM2CHRM3SMN1; SMN2 | |
| SCHEMBL3646231 | 0.81 | SMN1; SMN2 (0.42) | BTKHRH3CHRM2CHRM3SMN1; SMN2 | |
| SCHEMBL4228795 | 0.81 | SMN1; SMN2 (0.42) | BTKHRH3CHRM2CHRM3SMN1; SMN2 | |
| SCHEMBL2174895 | 0.81 | BTK (0.49) | BTKHRH3CHRM2CHRM4CHRM3 | |
| Ammonia Solution, Strong SCHEMBL5902021 | 0.80 | ALDH1A1 (0.41) | KMT2ACYP3A4CYP2D6TSHR | |
| SCHEMBL1296976 | 0.79 | HRH3 (0.41) | BTKHRH3CHRM2CHRM3JAK1 | |
| SCHEMBL31142979 | 0.79 | BTK (0.33) | BTKHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | BTK 253/4885HRH3 1228/4885CHRM2 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.